Stock Analiz

Monte Rosa Therapeutics, Inc. GLUE

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026

$9.37Market cap $801M
Open the interactive analysis →

Monte Rosa Therapeutics, Inc. (GLUE) is a healthcare company listed in the US with a market value of about $801M. In the twelve months to September 30, 2026 it had revenue of $70M and net income of -$131M, a net margin of -186.2%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -29%.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. It was profitable in 0 of the last 6 years in our data. Its share count rose by 76% over three years (dilution for shareholders). It spends 114% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth3/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S11.4
P/B1.6
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-21.8%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)63.5%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-63.7%
ROIC (5-yr avg.)-29.0%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 6 years

Fiscal yearTTM202520242023202220212020
Revenue$70M$124M$76M$0———
Net income-$131M-$39M-$73M-$135M-$109M-$74M-$36M
Free cash flow-$174M-$27M$38M-$63M-$105M-$69M-$26M
EPS (diluted)$-1.40$-0.46$-0.98$-2.63$-2.30$-2.96$-23.65
Net margin-186.2%-31.2%-96.1%————
ROIC—-19.4%-24.1%-50.2%-35.3%-16.2%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 8 analysts is $25.38, 171% above the current price; targets range from $15.00 to $37.00; the consensus rating is “Strong buy”; expected EPS is $-1.02 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Monte Rosa Therapeutics pay a dividend?

Not currently.

Is Monte Rosa Therapeutics a good stock to buy?

We do not give buy or sell advice. Monte Rosa Therapeutics scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.